385 related articles for article (PubMed ID: 26586297)
1. Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Im W; Ban JJ; Chung JY; Lee ST; Chu K; Kim M
Sci Rep; 2015 Nov; 5():16887. PubMed ID: 26586297
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease.
Ban JJ; Chung JY; Lee M; Im W; Kim M
Biochem Biophys Res Commun; 2017 Jun; 488(2):316-321. PubMed ID: 28495533
[TBL] [Abstract][Full Text] [Related]
3. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
4. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
Lu B; Palacino J
FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
[TBL] [Abstract][Full Text] [Related]
5. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
[TBL] [Abstract][Full Text] [Related]
6. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.
Liu KY; Shyu YC; Barbaro BA; Lin YT; Chern Y; Thompson LM; James Shen CK; Marsh JL
Hum Mol Genet; 2015 Mar; 24(6):1602-16. PubMed ID: 25398943
[TBL] [Abstract][Full Text] [Related]
8. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
9. Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease.
Ragauskas S; Leinonen H; Puranen J; Rönkkö S; Nymark S; Gurevicius K; Lipponen A; Kontkanen O; Puoliväli J; Tanila H; Kalesnykas G
PLoS One; 2014; 9(12):e113317. PubMed ID: 25469887
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease Development.
Bayram-Weston Z; Jones L; Dunnett SB; Brooks SP
PLoS One; 2016; 11(5):e0155834. PubMed ID: 27196694
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
Morozko EL; Ochaba J; Hernandez SJ; Lau A; Sanchez I; Orellana I; Kopan L; Crapser J; Duong JH; Overman J; Yeung S; Steffan JS; Reidling J; Thompson LM
J Huntingtons Dis; 2018; 7(4):321-335. PubMed ID: 30452420
[TBL] [Abstract][Full Text] [Related]
12. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
13. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
14. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
15. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
[TBL] [Abstract][Full Text] [Related]
16. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
Lee CY; Cantle JP; Yang XW
FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
[TBL] [Abstract][Full Text] [Related]
18. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
